Vanda Pharmaceuticals' board is unimpressed with takeover offers from both Cycle Pharma and Future Pak, saying they both “substantially undervalue” the company.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.